J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints
OWS Leader Predicts Success
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
You may also be interested in...
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.